卡铂诱导NF1小鼠模型视神经少突胶质细胞丢失并损害髓鞘微结构
该临床前研究在Nf1突变小鼠中评估卡铂对视神经少突胶质细胞的肿瘤非依赖性毒性,发现临床相关剂量卡铂导致少突胶质细胞丢失和髓鞘结构损害,而长春碱类或司美替尼未观察到该效应;补充膳食胆固醇、氯马斯汀或PLX5622可缓解该毒性,且后两者降低Nf1突变视路胶质瘤细胞活力。
要点
- 卡铂可致Nf1+/-小鼠视神经少突胶质细胞丢失和髓鞘损害,长春碱类或司美替尼未见此效应
- 卡铂下调胆固醇合成基因并降低视神经胆固醇水平,补胆固醇可恢复少突胶质细胞数量
- 氯马斯汀或PLX5622可减轻卡铂所致少突胶质细胞丢失,并降低肿瘤细胞活力
核心结论
- 卡铂对Nf1突变视神经具有少突胶质细胞毒性,该毒性可通过氯马斯汀、PLX5622或卡铂后膳食胆固醇补充减轻。
研究设计与样本
- 研究使用卡铂或溶媒处理的Nf1+/-小鼠及Nf1突变视路胶质瘤细胞,分别评估干预措施在体内对视神经少突胶质细胞的作用及体外对肿瘤细胞生长的影响。
主要发现
- 临床相关剂量卡铂诱导Nf1+/-小鼠视神经少突胶质细胞丢失和髓鞘结构损害,而长春碱类或MEK抑制剂司美替尼处理未观察到此效应。
- 卡铂下调胆固醇生物合成关键基因并降低卡铂暴露的Nf1+/-视神经胆固醇水平,卡铂后膳食胆固醇补充可恢复少突胶质细胞数量。
- 卡铂增加Nf1+/-视神经中单核细胞(小胶质细胞/巨噬细胞)密度。
- 使用PLX5622(CSF1R抑制剂)减少单核细胞数量或使用氯马斯汀促进少突胶质细胞生成与存活,可减轻卡铂所致少突胶质细胞丢失。
- PLX5622和氯马斯汀可降低Nf1突变视路胶质瘤肿瘤细胞活力。
临床怎么用
- 在NF1相关视路胶质瘤患儿接受含卡铂化疗时,需关注卡铂对少突胶质细胞和髓鞘的潜在毒性。
- 氯马斯汀、PLX5622或膳食胆固醇补充是临床前研究中减轻卡铂视神经毒性的候选策略,尚需临床验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Vision impairment is a significant concern for children with Neurofibromatosis type 1 (NF1)-associated optic pathway glioma (OPG). While carboplatin-containing chemotherapy is often first-line therapy for NF1-OPG, it does not consistently improve visual function. Furthermore, chemotherapy is associated with altered white matter microstructure in individuals with NF1-OPG, suggesting a detrimental effect on oligodendroglia. We analyzed the tumor-independent effects of carboplatin on oligodendrocytes in Nf1-mutant mice and evaluated pharmacological strategies for reducing this chemotherapy-associated toxicity. METHODS: Carboplatin- or vehicle-treated Nf1+/- mice or Nf1-mutant optic glioma cells were employed to assess the effects of restorative interventions on optic nerve oligodendrocytes in vivo and tumor cell growth in vitro, respectively. RESULTS: Clinically relevant carboplatin dosing induced oligodendrocyte loss and impaired myelin sheath structure in the optic nerves of Nf1+/- mice, an effect not observed following vinca alkaloids or MEK inhibitor (selumetinib) treatment. Carboplatin downregulates genes essential for cholesterol biosynthesis and decreases cholesterol levels in carboplatin-exposed Nf1+/- optic nerves, such that dietary cholesterol supplementation after carboplatin exposure restored oligodendrocyte numbers. Carboplatin also increases the density of monocytes (microglia/macrophages) in the Nf1+/- optic nerves. Using PLX5622 (a CSF1R inhibitor) to reduce monocytes numbers or using clemastine to promote the generation and survival of oligodendrocytes, alleviated the oligodendrocyte loss caused by carboplatin treatment. Notably, PLX5622 and clemastine reduced the viability of Nf1-mutant optic glioma tumor cells. CONCLUSIONS: Our findings demonstrate that carboplatin induces oligodendroglial toxicity in Nf1-mutant optic nerves, which can be mitigated by clemastine, PLX5622, or dietary cholesterol following carboplatin exposure. Children with Neurofibromatosis Type 1 (NF1) can develop brain tumors along the visual pathway, called Optic Pathway Glioma (OPG), which may impair vision. Chemotherapy, often including the drug carboplatin, is commonly used to slow tumor growth. However, treatment does not always improve vision, and some children continue to experience vision loss. In this study, we asked whether carboplatin might also harm non-tumor cells in the optic nerve that are important for vision. In particular, we focused on oligodendrocytes, specialized support cells that produce myelin - the protective coating that helps nerve fibers efficiently carry visual information from the eyes to the brain. Using mouse models of NF1, we found that carboplatin reduced oligodendrocyte numbers and damaged myelin in the optic nerve. These findings suggest that chemotherapy-related toxicity to the optic nerve may contribute to visual problems, in addition to the effects of the tumor itself. We also tested potential strategies to protect the optic nerve after carboplatin treatment. In the NF1 mouse models, a cholesterol-enriched diet, clemastine, and PLX5622 helped preserve or restore oligodendrocytes. Clemastine and PLX5622 also reduced the growth of NF1-OPG tumor cells in culture. Together, these preclinical findings suggest that combining chemotherapy with treatments that protect oligodendrocytes and myelin may be a promising strategy to reduce optic nerve toxicity while still controlling tumor growth in NF1-associated optic pathway glioma.
引用
- Aghoghovwia BE, Ban K, Stavropoulos D, et al. Carboplatin induces optic nerve oligodendrocyte loss and impairs myelin sheath microstructure in a mouse model of neurofibromatosis type 1 (NF1). Neuro Oncol. 2026. PMID: 42482124. doi:10.1093/neuonc/noag163
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。